The FDA's poor oversight of postmarketing studies

被引：0

|

作者：

不详

机构：

来源：

LANCET | 2009年 / 374卷 / 9701期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1568 / 1568

页数：1

相关论文

共 50 条

[21] FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients
Dauner, Daniel G.
Dauner, Kim Nichols
Peterson, Annalisa L. H.
[J]. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2020, 16 (06): : 844 - 847
[22] US FDA Postmarketing Requirements and Commitments: A Systematic Assessment of Clinical Pharmacology Studies and Their Impact on US FDA Prescribing Information
Ridge, Sarah
Guinn, Daphne
Fletcher, Elimika Pfuma
Zineh, Issam
Madabushi, Rajanikanth
Ramamoorthy, Anuradha
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (06): : 695 - 703
[23] Report criticizes lack of FDA oversight
Mitka, Mike
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (08): : 920 - 922
[24] Expansion of FDA oversight power sought
不详
[J]. ISSUES IN SCIENCE AND TECHNOLOGY, 2008, 24 (02) : 17 - 18
[25] FDA BOOSTS OVERSIGHT OF IMPORTED FOOD
不详
[J]. CHEMICAL & ENGINEERING NEWS, 2013, 91 (31) : 24 - 24
[26] A Brief History of FDA Compounding Oversight
Shulman, Stanford T.
[J]. PEDIATRIC ANNALS, 2013, 42 (01):
[27] Regulation: FDA revises postmarketing reporting requirements
Rios, Maribel
[J]. Pharmaceutical Technology, 2007, 31 (11)
[28] Postmarketing requirements for new drugs approved by the FDA
[J]. Reactions Weekly, 2022, 1895 (1) : 8 - 8
[29] US FDA posts report on postmarketing surveillance
[J]. Reactions Weekly, 2019, 1766 (1) : 3 - 3
[30] Tofacitinib dosage to be modified in FDA postmarketing trial
[J]. Reactions Weekly, 2019, 1742 (1) : 6 - 6

← 1 2 3 4 5 →